1 Love, J. Paying for Healthcare R&D: Carrots and Sticks, http://www.cptech.org/ip/health/rnd/index.html) accessed 10 October 2003.

2 Hardin, G. 1968 The Tragedy of the Commons Science, 162:1243-1248.

3 Heller, MA. & Eisenberg, RS. 1998 Can Patents Deter Innovation? The Anticommons in Biomedical Research Science, 280: 698-701

4 Ye, X. Al-Babili, S. Klöti, A. Zhang, J. Lucca, P. Beyer, P. Potrykus, 2000, I, Engineering the provitamin A (ß-carotene) biosynthetic pathway into (carotenoid-free) rice endosperm Science, 287:303-305.

5 Love, J. A 3-drug fixed-dose ARV combination for USD 250? e-drug, May 9, 2001, available at pharm-policy@lists.essential.org

6 Attaran, A. and Gillespie-White, L. 2001 Do patents for antiretroviral drugs constrain access to AIDS treatment in Africa? J. Am. Med. Assn., 286:1886-92.

7 UNAIDS 2000 Report on the global HIV/AIDS epidemic (http://www.unaids.org/epidemic_update/report/index.html#table) accessed 11 November 2002.

8 Blackwell, JM and Melville, SE. 1999 Status of protozoan genome analysis: trypanosomatids Parasitology, 118 (Suppl): S11-4.

9 Degrave, WM. Melville, S. Ivens, A. Aslett, M. 2001 Parasite genome initiatives Int J Parasitol. 31:532-6.

10 Gardner, MJ. et al. 2002 Genome sequence of the human malaria parasite Plasmodium falciparum, Nature, 419:498-511.

11 Holt, RA. et al. 2002 The genome sequence of the malaria mosquito Anopheles gambiae Science, 298:129-49.

12 Butler, D. Drive for patent-free innovation gathers pace 10 July 2003, 118 Nature vol. 424 (http://www.nature.com/nature).

13 Kaplan, WA. and Krimsky, S. 2001 Patentability of Biotechnology Inventions Under The PTO Utility Guidelines: Still Uncertain After All These Years? J. Biolaw & Business Supplement, 2001: 34-48.

14 Madey v. Duke University, Fed. Cir. 2001 (Research exception to patent infringement liability does not apply to research performed in universities) (http://www.ll.georgetown.edu/federal/judicial/fed/opinions/01opinions/01-1567.html) accessed 5 October 2001. This case is being appealed to the US Supreme Court.

15 SNP consortium website, Single Nucleotide Polymorphisms for Biomedical Research (http://snp.cshl.org) accessed 4 October 2003.

16 SEMATECH website (http://www.sematech.org) accessed 4 September 2003.

17 Consumer Project on Technology: Compulsory Licensing (http://www.cptech.org/ip/health/cl/cptech) accessed 6 October 2003.

18 Reichman, JH. and Hasenzahl, C. 2002 Non-voluntary Licensing of Patented Inventions: The Canadian Experience UNCTAD/ICTSD Capacity Building Project on Intellectual Property Rights and Sustainable Development.

19 Blood Screening HIV Probe License Agreement Between Chiron Corporation F. Hoffmann-La Roche Ltd. and Roche Molecular Systems, Inc. Article 5 (http://lists.essential.org/pipermail/ip-health/2002-February/002709.html).

20 Clark, J. Piccolo, J. Stanton, B. Tyson, K. 2000 Patent Pools: A Solution to the Problem of access in Biotechnology Patents? (http://www.uspto.gov/web/offices/pac/dapp/opla/patentpool.pdf) U.S. Patent and Trademark Office, Accessed October 10, 2003.

21 The Fourth Ministerial Conference, Doha, Qatar Meeting, World Trade Organization, November 2001 (http://www.wto.org/english/thewto_e/minist_e/min01_e/min01_e.htm) accessed 3 September 2002.

22 The dispute over setting aside patents that limit cheap drug supplies became the key issue. Particularly in light of Canada’s overriding the Bayer patent on ciprofloxacin with regard to the anthrax bioterrorism scare in late 2001 and the U.S. refusing to override the patent, certain developing countries were asking if there was a double standard at work. In the United States, federal statutes under the U.S Clean Air Act and the Atomic Energy Act, mandate compulsory licensing under certain circumstances.

23 CAMBIA (http://www.cambia.org.au/main/ipwhy_inv.htm) access 12 November 2003.

24 February 2001 IP Clearinghouse Mechanisms for Agriculture(http://www.farmfoundation.org/pubs2/berkeleyagbioworkshop.pdf) accessed 12 November 2003.

25 Looasreesuwon, S. Chuylay, JD. Canfield, CH. Hutchinson, DB. 1999 Malarone® (atovaquone and proguanil (HCL): a review of its clinical development for treatment of malaria Am. J. Trop. Med. Hyg. 60: 533-54.

26 Report of the Workshop on Differential Pricing & Financing of Essential Drugs April 2001, Hosbjor, Norway, WHO/WTO Secretariat Workshop, Høbsjør, Norway, (http://www.who.int/medicines/docs/par/equitable_pricing.doc) Background papers to this conference (http://www.wto.org/english/tratop_e/trips_e/wto_background_e.doc) Accessed 15 November 2001.